Biofortuna Ltd.
Biofortuna is a specialist contract development and manufacturing organization providing genomic services, custom development, and manufacturing support to the IVD, consumer health, life sciences, and pharma biotech sectors. The Company is ISO 17025 and ISO 13485 accredited and FDA registered. Biofortuna provides a complete solution for diagnostic manufacturing companies - design and development, freeze-drying (lyophilization), manufacturing, dispensing, and kitting.
Product News
Microbiology Product Areas
ClinicalNOTE: The products listed in this section may not be approved for clinical diagnostic use in your jurisdiction. You must assume these products are unregulated and therefore cannot be used for routine testing and reporting of results unless otherwise stated. | ||
| Diagnostic Manufacturing | Show all suppliers | |
Pharmaceutical | ||
| PCR | Show all suppliers | |
Get our eNewsletter
Over 7,000 microbiology professionals get our weekly eNewsletter - subscribe now and find out why!
LATEST MICROBIOLOGY NEWS
- Stop Worrying, Prepare Your Half Fraser Broth in 1 Step With Condalab!
- Steam Control GST E6 SS (BA coupons)
- Change in Board of Directors of MBV AG
- Environmental Swabbing Assay That Simultaneously Detects Both Salmonella and Listeria in One Test
- Rapid Micro Biosystems® Growth Direct® System Detects Mold in as Little as 1 Day
- Priorclave Simplifies Autoclave Selection Process
- Microbiologics Announces New CEO
- MAESTRIA™, a New Generation Microbiology Middleware Optimizes Laboratory Workflow
- How an EMS Can Help You Meet Annex 1
- Is Your Environmental Monitoring In Line With The New Annex 1?
MICROBIOLOGY EVENTS
- HypoxEU Virtual Seminar
- Using VITAL Reference Doses for Allergen Labelling
- GENAP Summit 2023
- 2023 PDA Annex 1 Workshop
- 7th Microbiome Movement - AgBioTech Summit
- Viable Air and Surface Sampling for Sterile Compounding Facilities
- Low Endotoxin Recovery/Masking - Hands-on Laboratory Training Course
- My Green Lab Europe 2023 Summit
- 2023 CMI International Microbiome Meeting (CIMM)
- Impact of New Version of Annex1 on Drug Substance and Drug Processes